Literature DB >> 12879151

Codelivery of a DNA vaccine and a protein vaccine with aluminum phosphate stimulates a potent and multivalent immune response.

Marcin Kwissa1, Erik B Lindblad, Reinhold Schirmbeck, Joerg Reimann.   

Abstract

The study explores the possibility of efficiently codelivering DNA vaccines and protein-based vaccines by formulation with aluminum phosphate (AlPO4). When mixed with aluminum adjuvants, plasmid DNA bound tightly onto aluminum hydroxide [Al(OH)3] but not to AlPO4. Different doses of DNA vaccines formulated with AlPO4 [but not Al(OH)3] induced enhanced humoral responses and supported priming of MHC class I restricted cellular immunity. Different proteins mixed with the plasmid DNA vaccine in the AlPO4 formulation did not impair its immunogenicity. Coinjection of two different vaccine-relevant antigens in the same AlPO4 formulation, one as a DNA vaccine and the other as a recombinant protein, elicited polyvalent, humoral, and cellular immune responses to all antigens delivered. The isotype profiles of the induced humoral responses and the cytokine profiles of the specifically primed T cell responses indicated that the combined vaccines supported copriming of Th1- and Th2-biased as well as balanced responses. These findings indicate that the AlPO4 adjuvant, a widely accepted adjuvant in human vaccination practice, can be used to combine protein- and DNA-based vaccination to prime an enhanced and balanced specific immunity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12879151     DOI: 10.1007/s00109-003-0452-9

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  28 in total

1.  The Th1/Th2 nature of concurrent immune responses to unrelated antigens can be independent.

Authors:  N Ismail; P A Bretscher
Journal:  J Immunol       Date:  1999-11-01       Impact factor: 5.422

Review 2.  DNA vaccines: immunology, application, and optimization*.

Authors:  S Gurunathan; D M Klinman; R A Seder
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

3.  Can we apply the TH1-TH2 paradigm to all lymphocytes?

Authors:  M Colonna
Journal:  Nat Immunol       Date:  2001-10       Impact factor: 25.606

Review 4.  Enhancing the immunogenicity of exogenous hepatitis B surface antigen-based vaccines for MHC-I-restricted T cells.

Authors:  R Schirmbeck; J Reimann
Journal:  Biol Chem       Date:  1999-03       Impact factor: 3.915

Review 5.  Type 1 and type 2: a fundamental dichotomy for all T-cell subsets.

Authors:  L L Carter; R W Dutton
Journal:  Curr Opin Immunol       Date:  1996-06       Impact factor: 7.486

6.  Enhanced type I immune response to a hepatitis B DNA vaccine by formulation with calcium- or aluminum phosphate.

Authors:  S Wang; X Liu; K Fisher; J G Smith; F Chen; T W Tobery; J B Ulmer; R K Evans; M J Caulfield
Journal:  Vaccine       Date:  2000-01-18       Impact factor: 3.641

7.  Direct ex vivo kinetic and phenotypic analyses of CD8(+) T-cell responses induced by DNA immunization.

Authors:  D E Hassett; M K Slifka; J Zhang; J L Whitton
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

8.  Priming biologically active antibody responses against an isolated, conformational viral epitope by DNA vaccination.

Authors:  Petra Riedl; Shereen El-Kholy; Jörg Reimann; Reinhold Schirmbeck
Journal:  J Immunol       Date:  2002-08-01       Impact factor: 5.422

9.  Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.

Authors:  R Wang; D L Doolan; T P Le; R C Hedstrom; K M Coonan; Y Charoenvit; T R Jones; P Hobart; M Margalith; J Ng; W R Weiss; M Sedegah; C de Taisne; J A Norman; S L Hoffman
Journal:  Science       Date:  1998-10-16       Impact factor: 47.728

10.  Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms.

Authors:  P S Walker; T Scharton-Kersten; A M Krieg; L Love-Homan; E D Rowton; M C Udey; J C Vogel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

View more
  10 in total

1.  Immune responses in DNA vaccine formulated with PMMA following immunization and after challenge with Leishmania major.

Authors:  Somayeh Zarrati; Mehdi Mahdavi; Fatemeh Tabatabaie
Journal:  J Parasit Dis       Date:  2014-08-31

2.  Novel DNA vaccine based on hepatitis B virus core gene induces specific immune responses in Balb/c mice.

Authors:  Yi-Ping Xing; Zu-Hu Huang; Shi-Xia Wang; Jie Cai; Jun Li; Te-Hui W Chou; Shan Lu
Journal:  World J Gastroenterol       Date:  2005-08-07       Impact factor: 5.742

3.  A conserved region of leptospiral immunoglobulin-like A and B proteins as a DNA vaccine elicits a prophylactic immune response against leptospirosis.

Authors:  Karine M Forster; Daiane D Hartwig; Fabiana K Seixas; Kátia L Bacelo; Marta Amaral; Cláudia P Hartleben; Odir A Dellagostin
Journal:  Clin Vaccine Immunol       Date:  2013-03-13

4.  A DNA fusion vaccine induces bactericidal antibodies to a peptide epitope from the PorA porin of Neisseria meningitidis.

Authors:  Delin Zhu; Jeannette N Williams; Jason Rice; Freda K Stevenson; John E Heckels; Myron Christodoulides
Journal:  Infect Immun       Date:  2007-10-29       Impact factor: 3.441

5.  Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge.

Authors:  Christopher S Morello; Kimberly A Kraynyak; Michael S Levinson; Zhijiang Chen; Kuo-Fen Lee; Deborah H Spector
Journal:  Vaccine       Date:  2012-09-01       Impact factor: 3.641

6.  Th1 Platform Immune Responses Against Leishmania major Induced by Thiol-Specific Antioxidant-Based DNA Vaccines.

Authors:  Fatemeh Tabatabaie; Mehdi Mahdavi; Sobhan Faezi; Abdolhossein Dalimi; Zohreh Sharifi; Lame Akhlaghi; Fatemeh Ghaffarifar
Journal:  Jundishapur J Microbiol       Date:  2014-02-01       Impact factor: 0.747

7.  Mechanism of immunopotentiation and safety of aluminum adjuvants.

Authors:  Harm Hogenesch
Journal:  Front Immunol       Date:  2013-01-10       Impact factor: 7.561

8.  DNA prime-protein boost based vaccination with a conserved region of leptospiral immunoglobulin-like A and B proteins enhances protection against leptospirosis.

Authors:  Karine M Forster; Daiane D Hartwig; Thaís L Oliveira; Kátia L Bacelo; Rodrigo Schuch; Marta G Amaral; Odir A Dellagostin
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-12-11       Impact factor: 2.743

Review 9.  Unraveling the enigma: elucidating the relationship between the physicochemical properties of aluminium-based adjuvants and their immunological mechanisms of action.

Authors:  Emma Shardlow; Matthew Mold; Christopher Exley
Journal:  Allergy Asthma Clin Immunol       Date:  2018-11-07       Impact factor: 3.406

10.  Strategies for simultaneous and successive delivery of RNA.

Authors:  Hanieh Moradian; Andreas Lendlein; Manfred Gossen
Journal:  J Mol Med (Berl)       Date:  2020-11-04       Impact factor: 4.599

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.